TCL Archive In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs By Cancer History Project January 17, 1992
TCL Archive ODAC Endorses Tamoxifen Trial, With Modification to Ensure Enrollment of Women At Higher Risk By Cancer History Project August 2, 1991
TCL Archive ODAC Oks Carboplatin As 1st Line Ovarian Therapy; Other Drugs By Cancer History Project July 12, 1991
TCL Archive ODAC Recommends Fludarabine Approval for Refractory CLL By Cancer History Project September 21, 1990
TCL Archive ODAC Rejects Amsacrine NDA, Renews Idarubicin By Cancer History Project September 14, 1990
PeopleSpotlight Article Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer By Cancer History Project October 4, 2024
Primary SourceSpotlight Article Iressa: Oncologic Drugs Advisory Committee Meeting Sept. 24, 2002 By FDA Oncology Center of Excellence June 21, 2024
ArticleSpotlight Article A Vote for Cancer: Tobacco Advertising and Presidential Elections By The Center for the Study of Tobacco and Society